SKVI (Skinvisible) ROCE % : 0.00% (As of Sep. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Skinvisible ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Skinvisible's annualized ROCE % for the quarter that ended in Sep. 2024 was 0.00%.

Skinvisible ROCE % Historical Data

The historical data trend for Skinvisible's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skinvisible ROCE % Chart

Skinvisible Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

Skinvisible Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Skinvisible ROCE % Calculation

Skinvisible's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.495	/	( ( (0.247 - 3.645)	+	(0.163 - 3.512) )	/ 2 )
	=	-0.495	/	( (-3.398	+	-3.349)	/ 2 )
	=	-0.495	/	-3.3735
	=	14.67 %

Skinvisible's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-0.476	/	( ( (0.163 - 4.024)	+	(0.149 - 4.644) )	/ 2 )
	=	-0.476	/	( ( -3.861	+	-4.495 )	/ 2 )
	=	-0.476	/	-4.178
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Skinvisible (OTCPK:SKVI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Skinvisible ROCE % Related Terms

Thank you for viewing the detailed overview of Skinvisible's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Skinvisible Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Skinvisible Inc (OTCPK:SKVI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6320 South Sandhill Road, Suite 10, Las Vegas, NV, USA, 89120

Website

https://www.skinvisible.com

Skinvisible Inc is a pharmaceutical research and development company that has developed and patented a polymer delivery system, Invisicare and formulated over forty topical skin products, which it out-licenses globally. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. The Company is also exploring new opportunities in large medical markets outside of the dermatology market such as obesity and other potential markets where a topical or transdermal solution would be a viable alternative.

Executives

St James David M	director	3395 S. JONES BLVD., #169, LAS VEGAS NV 89146
Doreen Mcmorran	10 percent owner	6320 S. SANDHILL RD UNIT 10, LAS VEGAS NV 89120
Brian Piwek	director	9014 GLENEAGLE DRIVE, BLAINE WA 98230
E Greg Mccartney	director	#307-15338 18TH AVENUE, SURREY BC A1 V4A 1W8
Jost Steinbruchel	director	7, RUE DES BATTOIRS, POBOX #214, 1211 GENEVA 4 V8 000000
Robert F Lutz	director, 10 percent owner
Terry Howlett	director, 10 percent owner, officer: President & Chief Exec.Officer	6320 S. SANDHILL ROAD, SUITE #10, LAS VEGAS NV 89120
Skinvisible Inc	director, 10 percent owner, officer: President	6320 S SANDHILL ROAD, SUITE 10, LAS VEGAS NV 89120
Lutz Family Trust	10 percent owner	8322 WEST TONTO LANE, PEORIA AZ 85382